Digestive System Neoplasm

cancer family

Identifier: CI-CAN-00000012
Entity page: /cancer/digestive-system-neoplasm ↗
Edges: 12,854

Neighbours: 15 genes33 drugs10 trials
Drawn: 58 of 58 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Digestive System Neoplasm approved for …APPROVED_FORderived15 of 39show all (up to 200)
← approved for	Fluorouracilsmall_molecule FDA (US) · approved · 2026-02-20 · Pancreatic Adenocarcinoma	—	approved	Pancreatic Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for	Gemcitabine

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

FGFR2 Fusion Infigratinib0 active / 4 trials
Curatedlevel Asensitivity· support 3civicObservedFGFR2 altered in 3% (41 / 1,370 cases)no approval record in this cancercontext: Cholangiocarcinoma
FGFR2 Fusion Infigratinib0 active / 4 trials
Curatedlevel Asensitivity· support 3civicObservedFGFR2 altered in 3% (41 / 1,370 cases)no approval record in this cancercontext: Cholangiocarcinoma
IDH1 R132 IvosidenibFDA US 2018-07-206 active / 9 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 10% (141 / 1,370 cases, largest of 2 cohorts)Regulatoryapproved for Cholangiocarcinomacontext: Cholangiocarcinoma
FGFR2 Fusion PemigatinibFDA US 2020-04-173 active / 11 trials
Curatedlevel Asensitivity· support 1civicObservedFGFR2 altered in 3% (41 / 1,370 cases)Regulatoryapproved for Cholangiocarcinoma (2 approval records)context: Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma
FGFR2 Fusion PemigatinibFDA US 2020-04-173 active / 11 trials
Curatedlevel Asensitivity· support 1civicObservedFGFR2 altered in 3% (41 / 1,370 cases)Regulatoryapproved for Cholangiocarcinoma (2 approval records)context: Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma
BRCA2 Loss-of-function OlaparibFDA US 2017-08-1717 active / 31 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 2.1% (29 / 1,370 cases)Regulatoryapproved for Pancreatic Adenocarcinomacontext: Pancreatic Adenocarcinoma
BRCA1 Loss-of-function OlaparibFDA US 2017-08-1717 active / 31 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Pancreatic Adenocarcinomacontext: Pancreatic Adenocarcinoma
NRG1 Fusion Zenocutuzumab-zbco0 active / 1 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for NRG1 in this cancerno approval record in this cancercontext: Pancreatic Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Digestive System Neoplasm investigated for …INVESTIGATED_FOR15 of 16show all (up to 200)
← investigated for	Trastuzumab Deruxtecanadc	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Trastuzumab Deruxtecanadc	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Trastuzumabmonoclonal_antibody	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Regorafenib Anhydroussmall_molecule	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Regorafenibsmall_molecule	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Pyrotinibsmall_molecule	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Oxaliplatinsmall_molecule	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Leucovorinsmall_molecule	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Fluorouracilsmall_molecule	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Alectinibsmall_molecule	unknown	2	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Tislelizumabmonoclonal_antibody	unknown	1	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Picoplatinsmall_molecule	unknown	1	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Pasireotideother	unknown	1	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Irinotecansmall_molecule	unknown	1	Digestive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Cisplatinsmall_molecule	unknown	1	Digestive System Neoplasm	1	Curated	chembl	graph →

Digestive System Neoplasm altered in cohorts of …ALTERED_INderived15 of 507show all (up to 200)
← altered in cohorts of	HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →

Digestive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 324show all (up to 200)
→ investigated in trials for	Gemcitabinesmall molecule 591 trials (102 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	591	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall_molecule 380 trials (114 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	380	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 376 trials (101 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	376	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall_molecule 368 trials (91 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	368	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 315 trials (112 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	315	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall_molecule 222 trials (60 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	222	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 212 trials (72 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	212	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall_molecule 207 trials (52 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	207	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 191 trials (12 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	191	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 189 trials (64 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	189	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 157 trials (54 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	157	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall_molecule 142 trials (39 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	142	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 140 trials (57 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	140	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 137 trials (31 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	137	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 112 trials (61 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neoplasm	112	Observed	clinicaltrials	graph →

Digestive System Neoplasm studied in …STUDIED_INderived10 of 11,968show all (up to 200)
→ studied in	NCT00423306Phase 2 · completed A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 11,968 trials mapped (3,387 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 11,968 trials mapped (3,387 active)	—	—	Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02598349Phase 2 · recruiting Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas · condition mapped CURATED_EXACT · 11,968 trials mapped (3,387 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03897543Phase 1/Phase 2 · completed ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma · condition mapped ALIAS · 11,968 trials mapped (3,387 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 11,968 trials mapped (3,387 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04396821Phase 1/Phase 2 · active not recruiting A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors · condition mapped CURATED_EXACT · 11,968 trials mapped (3,387 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · condition mapped CURATED_BROADER · 11,968 trials mapped (3,387 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04605913Phase 1/Phase 2 · active not recruiting Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC · condition mapped CURATED_BROADER · 11,968 trials mapped (3,387 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04751370Phase 2 · active not recruiting Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer · condition mapped CURATED_BROADER · 11,968 trials mapped (3,387 active)	—	—	Malignant Rectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05176223Phase 2 · completed 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer · condition mapped CURATED_BROADER · 11,968 trials mapped (3,387 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →